10 completed, 3 active not recruiting, 3 terminated, 1 no longer available. 8 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Active not recruiting 3, Terminated 1 |
| Phase 1 | 7 | Completed 5, Terminated 2 |
| Phase 3 | 1 | Completed 1 |
Follow KRAS Gene Mutation: new trials by email Literature Review of KRAS Gene Mutation trials Research Report on KRAS Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer Futibatinib and Binimetinib - Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Taiho Oncology, Inc. | 38 | 2021-09-20 | 2024-09-19 |
| Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas TVB-2640 - KRAS Gene Mutation | Phase 2 | Active not recruiting | David E Gerber | 18 | 2019-09-11 | 2026-05-22 |
| Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer SHR-1210, Apatinib, Pemetrexed - NSCLC Stage IV, KRAS Gene Mutation | Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 25 | 2019-07-11 | 2025-07-04 |
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance] - Solid Tumors, NSCLC | Phase 1 / Phase 2 | Completed | Calithera Biosciences, Inc | 53 | 2019-06-25 | 2022-09-19 |
| Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation Onvansertib, Bevacizumab, FOLFIRI - Metastatic Colorectal Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Cardiff Oncology | 68 | 2019-06-24 | 2025-03-04 |
| Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG - Non Small Cell Lung Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 12 | 2018-10-09 | 2025-05-16 |
| Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Methotrexate, Pharmacokinetic Study, Regorafenib - KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Completed | Stanford University | 22 | 2018-08-14 | 2023-08-01 |
| Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Pembrolizumab, Trametinib - KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 1 | Completed | Jonathan Riess | 15 | 2018-06-26 | 2025-05-21 |
| OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - Plasma circulating DNA analysis - Colorectal Cancer Metastatic, Circulating Tumor DNA | Completed | Karen-Lise Garm Spindler | 49 | 2018-06-01 | 2023-02-03 | |
| Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer Laboratory Biomarker Analysis, Panitumumab, Trametinib - EGFR NP_005219.2:p.S492R, KRAS Gene Mutation | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 59 | 2017-12-29 | 2026-07-16 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Terminated | M.D. Anderson Cancer Center | 84 | 2017-10-31 | 2026-07-22 |
| Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. Binimetinib, Pemetrexed, Cisplatin - Advanced Non-small Cell Lung Cancer, KRAS Gene Mutation | Phase 1 | Completed | Swiss Cancer Institute | 18 | 2017-04-12 | 2021-07-14 |
| Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Docetaxel, Laboratory Biomarker Analysis, Trametinib - KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2016-07-18 | 2026-10-26 |
| Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients Lung Neoplasms, KRAS Gene Mutation | Completed | Hospital Erasto Gaertner | 130 | 2014-04-01 | 2019-02-22 | |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation | Completed | Intergroupe Francophone de Cancerologie Thoracique | 17664 | 2012-04-01 | 2023-07-21 | |
| I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Chemotherapy, Panitumumab - Infiltrating Urothelial Carcinoma, KRAS Gene Mutation | Phase 3 | Completed | UNICANCER | 133 | 2010-06-01 | 2021-03-09 |
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer Onvansertib, Bevacizumab, FOLFIRI - Metastatic Colorectal Cancer, KRAS Gene Mutation | No longer available | Cardiff Oncology | 2024-02-12 |
Carcinoma, Non-Small-Cell Lung (7) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Brain Neoplasms (1) · Neoplasm Metastasis (1)
Neoplasms (13) · Neoplasms by Site (12) · Lung Diseases (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9) · Thoracic Neoplasms (9) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Neoplasms (6) · Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3)
trametinib (5) · Bevacizumab (2) · IFL protocol (2) · Panitumumab (2) · Pemetrexed (2) · binimetinib (2) · onvansertib (2) · palbociclib (2) · CB-839 (1) · Carboplatin (1) · Cisplatin (1) · Docetaxel (1) · Drug Therapy (1) · Everolimus (1) · Methotrexate (1)
Cardiff Oncology (2) · M.D. Anderson Cancer Center (2) · Calithera Biosciences, Inc (1) · David E Gerber (1) · Hospital Erasto Gaertner (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Jonathan Riess (1) · Karen-Lise Garm Spindler (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Stanford University (1) · Swiss Cancer Institute (1) · Taiho Oncology, Inc. (1) · UNICANCER (1)
United States (10) · France (2) · Brazil (1) · China (1) · Denmark (1) · Switzerland (1)
Christine Parseghian (1) · David Gerber, MD (1) · Emil Kuriakose, MD (1) · Fabrice Barlesi, PhD, MD (1) · Heather Wakelee (1) · Jianjun Zou, MD, PhD (1) · Jonathan Riess (1) · Karen-Lise G Spindler (1) · Kathryn Arbour, MD (1) · Sarina A Piha-Paul (1) · Shirish M Gadgeel (1) · Shun Lu, MD, PhD (1) · Thais A Almeida, MD (1)
PMID 26777916, PMID 34646387, PMID 35154704, PMID 37233987, PMID 37314501, PMID 38231047, PMID 39475591, PMID 42149426
2009 (1), P30CA093373 (1), U10CA180888 (1)